Cellectis SA (CMVLF) AI Stock Analysis

10 Followers

Cellectis SA

(Other OTC:CMVLF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

In Vivo Gene-Editing PipelineThe transition to single-injection in vivo gene-editing therapies creates potential for durable treatment effects and a differentiated pipeline. Preclinical activity across HEAL-101 and HEAL-201 supports continued clinical advancement and could broaden future commercial opportunities if human results validate the approach.

Negative Factors

Revenue Dependence and DeclineThe sharp revenue decline highlights dependence on collaboration activity rather than recurring product sales, leaving results exposed to partner program timing. Until the new pipeline matures, volatile collaboration income may make funding research and forecasting operating performance more difficult.

Cellectis SA (CMVLF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $250.97M
Dividend Yield: ―
Average Volume (3M): 5,680
Price to Earnings (P/E): -1.8
Beta (1Y): -0.48
Revenue Growth: 0.50%
EPS Growth: -14.88%
Country: US
Employees: 227
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric...

Cellectis SA Earnings Call Summary

Earnings Call Date:Nov 13, 2026(Q3-2026)|% Change Since:4.93%|Next Earnings Date:Mar 04, 2027

Earnings Call SentimentPositive

The call was strategically optimistic, centered on the transition to in vivo gene editing and encouraging preclinical results for HEAL-101 and HEAL-201. The company reiterated clinical timelines, described its LNP safety and prior clinical experience favorably, and expects cash runway into the second half of 2028. These positives were offset by the discontinuation of legacy cell therapy programs, planned headcount reductions, a substantial decline in revenue, lower cash and financial assets, and restructuring-related expenses. Overall, the number and strength of the stated pipeline and financing highlights outweighed the challenges.

Positive Updates

Strategic Transformation Toward In Vivo Gene Editing

Cellectis has transformed into an in vivo gene editing company focused initially on severe dyslipidemias, with HEAL-101 and HEAL-201 designed as single-injection therapies with the potential for long-lasting effects.

Negative Updates

Legacy Cell Therapy Programs Discontinued

Cellectis stopped development of the lasme-cel and eti-cel clinical programs. Enrollment has stopped, site closeout activities are underway, and treated patients will continue to be monitored under protocol-specified follow-up requirements.

Company Guidance

Cellectis said the investigator-initiated trial for HEAL-101 in China is on track, with preliminary clinical data expected in the second half of 2027; dose escalation is expected to start in Q1, the starting dose is anticipated to be effective, and by the end of year the company expects to start seeing the nine-month type of durability of effect. HEAL-201 is planned to enter phase I, with preliminary clinical data expected in the first half of 2028, while LDL-C reduction data will be provided in June. The company currently expects global headcount to be reduced by up to 70% from its pre-transition level over the course of 2026 and 2027, and expects to have a cash runway into the second half of 2028. Management expects HEAL-101 efficacy to be at least as good as the current treatments, is targeting the number of patients hitting under that target of 500, and estimates the target population at about 1.1 million across U.S. and EU5, or EU4 plus U.K.

Cellectis SA Risk Analysis

Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Cellectis SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CMVLF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:IPH	48Neutral	EUR 148.11M	-2.35	152.56%	―	-29.48%	7.91%
FR:TNG	48Neutral	EUR 203.14M	-4.31	-29.36%	―	189.81%	38.50%
FR:NANO	47Neutral	EUR 1.48B	-25.36	89.71%	―	―	―
FR:MAAT	38Underperform	EUR 19.99M	-0.54	―	―	-19.02%	10.39%
FR:OSE	37Underperform	EUR 40.04M	-1.02	-96.73%	―	-96.25%	-197.89%

* Healthcare Sector Average

Performance Comparison

CMVLF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CMVLF	Cellectis SA	1.17	-3.87	-76.79%
FR:IPH	Innate Pharma S.A.	1.20	-0.37	-23.37%
FR:NANO	Nanobiotix SA	27.90	8.34	42.64%
FR:TNG	Transgene SA	0.72	-0.58	-44.75%
FR:OSE	OSE Immunotherapeutics	1.73	-3.97	-69.60%
FR:MAAT	MaaT Pharma	1.03	-3.46	-77.10%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cellectis SA AI Stock Analysis